SCHEMBL4033293

SCHEMBL4033293

CCCn1nc(-c2ccc(OC)cc2C)c2cccc(Cl)c21

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.54
CRHR1 P34998 15/20 0.44
TLR8 Q9NR97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407288 0.87 ESR1 (0.52) ESR1CRHR1
SCHEMBL4030093 0.87 CRHR1 (0.44) ESR1CRHR1TLR8
SCHEMBL4032692 0.85 ESR1 (0.53) ESR1CRHR1
SCHEMBL4033330 0.84 ESR1 (0.69) ESR1CRHR1
SCHEMBL4031926 0.84 ESR1 (0.55) ESR1CRHR1
SCHEMBL4027997 0.82 ESR1 (0.73) ESR1
SCHEMBL1407179 0.80 CRHR1 (0.40) ESR1CRHR1TLR8
SCHEMBL4028791 0.80 ESR1 (0.50) ESR1CRHR1
SCHEMBL4033497 0.76 ESR1 (0.54) ESR1CRHR1
SCHEMBL4196898 0.76 ESR1 (0.45) ESR1CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1542976-B1 SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES WYETH CORP (US) 2009-02-04 EP disclosed
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols WYETH (US) 2007-09-27 US disclosed
US-7241791-B2 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2007-07-10 US disclosed
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols WYETH (US) 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225349-A1 Substituted 4-(Indazol-3-yl)phenols INSR, TNNI3, INSRR ESR1 1028/4885CRHR1 2217/4885TLR8 288/4885
US-20040167127-A1 Substituted 4-(indazol-3-yl)phenols INSR, MSR1, TNNI3 ESR1 2487/4885CRHR1 2181/4885TLR8 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.